Abstract：【Objective】 To explore the effect of simvastatin combined with thromboplastin on cerebral thrombosis patients and its influence on coagulation factor level. 【Methods】 A total of 108 cerebral thrombosis patients admitted to our hospital from July 2016 to July 2018 were selected. According to simple random method, patients were divided into the control group (n=54) and the research group (n=54),The control group was treated with Agkistrodon halys antithrombotic enzyme. The research group was treated with simvastatin in addition to the drug of the control group. The clinical efficacy, changes of carotid intima-media thickness (CIMT), plaque area, coagulation factor, coagulation time, blood lipid index, stroke scale of the National Institutes of Health (NIHSS) and the occurrence of adverse reactions in both groups were compared before and after treatment.【Results】 The total effective rate of the research group was higher than that of the control group (92.59% vs 68.52%, χ2=18.494; P<0.05). Before treatment, there was no significant difference in CIMT, plaque area, coagulation factor, coagulation time, blood lipid index between the two groups (P>0.05). After treatment, the CIMT, plaque area, coagulation factors, coagulation time, low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) of the two groups were all lower than those before treatment (P<0.05), except that the high density lipoprotein cholesterol (HDL-C) levels of the two groups were higher than before treatment (P<0.05). Of which, the above indicators of the research group were better than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).【Conclusion】 Simvastatin combined with antithrombotic enzyme can improve the therapeutic effect of cerebral thrombosis, reduce the level of coagulation factors and improve blood lipid metabolism and neurological function without significantly increasing adverse reactions.
[1] Vecht L, Zuurbier SM, Meijers JCM,et al. Elevated factor VIII increases the risk of cerebral venous thrombosis: a case-control study[J].J Neurol,2018,265(7):1612-1617. [2] 贡京京, 高鸿雁, 宋华淼, 等. 不同溶栓时间窗信息对脑梗死患者溶栓决策行为的影响[J].中华行为医学与脑科学杂志, 2016, 25(7):605-608. [3] 杜瑞雪,叶平,蔡剑鸣,等. 长期调脂治疗对颈动脉粥样硬化斑块成分的影响[J].中华老年心脑血管病杂志,2018,20(7):696-699. [4] 王晓红. 辛伐他汀对急性缺血性脑卒中疗效的临床研究[J].中国医药导刊,2016,18(11):1142-1143. [5] 《中华健康管理学杂志》编辑委员会, 中华医学会健康管理学分会, 全国脑血管病防治研究办公室. 脑血管健康管理与脑卒中早期预防专家共识[J].中华健康管理学杂志, 2017, 11(5):397-407. [6] Naess H, Kurtz M, Thomassen L, et al. Serial NIHSS scores in patients with acute cerebral infarction[J].Acta Neurol Scand,2016,133(6):415-420. [7] Zimny A, Dziadkowiak E, Bladowska J, et al. Cerebral venous thrombosis as a diagnostic challenge: Clinical and radiological correlation based on the retrospective analysis of own cases[J].Adv Clin Exp Med,2017,26(7):1113-1122. [8] Zang Y, Hou J, Wang LY. Therapeutic effect of tenecteplase on treatment of cerebral arterial thrombosis: a meta-analysis[J].Eur Rev Med Pharmacol Sci,2016,20(20):4369-4379. [9] 卫杰,孔晓东. 奥扎格雷钠联用降栓酶治疗急性脑血栓患者的临床疗效观察[J].海军医学杂志,2017,38(2):126-127. [10] Miyakoshi A, Toda H, Hayase M, et al. Anticoagulant therapy for recurrent in-stent thrombosis following carotid artery stenting: A case report[J].Interv Neuroradiol,2017,23(5):521-526. [11] 刘志军, 姚海针. 辛伐他汀与瑞舒伐他汀应用于缺血性脑卒中患者临床治疗中的效果对比分析[J].世界中医药, 2015,10(1):671. [12] 王映林,李青叶. 辛伐他汀对脑梗死患者神经功能及预后的影响[J].中国药房,2017,28(26):3708-3710. [13] 尤一萍, 何旻. 辛伐他汀或阿托伐他汀联合依达拉奉对急性脑梗死颈动脉斑块及踝肱指数的影响[J].医学临床研究, 2018,35(1):145-147. [14] 陈新悦, 毕国荣, 李双, 等. von Willebrand因子和凝血因子Ⅷ 水平与急性脑梗死的临床转归[J].中国神经精神疾病杂志, 2016, 42(1):22-28. [15] 姜文理,金佩佩,任懿倩,等. 凝血因子Ⅷ和细胞因子水平与脑卒中的相关性分析[J].检验医学,2017,32(6):467-470.
2020, Vol. 37 
